High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. (2021)

First Author: Cresswell FV
Attributed to:  Immunomodulation and Vaccines funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciab162

PubMed Identifier: 33693537

Publication URI: http://europepmc.org/abstract/MED/33693537

Type: Journal Article/Review

Volume: 73

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 5

ISSN: 1058-4838